Experimental basis and clinical experience with non-cross-resistant combinations in solid tumours.
Experimental studies on anticancer drug resistance have shown that cisplatin and alkylating agents have a very low level of cross resistance towards heterocyclic agents such as anthracyclines, podophyllotoxins and vinca alkaloids. Based on this and on the model of Goldie and Coldman protocols using sequentially alternating non-cross-resistant combinations were given in testicular cancer, sarcomas and small cell bronchogenic carcinomas. Preliminary clinical results are presented here.
D000818:Animals; D000903:Antibiotics, Antineoplastic; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy; D018288:Carcinoma, Small Cell / Q000188:drug therapy; D002460:Cell Line; D002945:Cisplatin / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D003606:Dacarbazine / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004351:Drug Resistance; D005047:Etoposide / Q000627:therapeutic use; D006801:Humans; D007069:Ifosfamide / Q000627:therapeutic use; D008297:Male; D009279:Naphthacenes / Q000627:therapeutic use; D012509:Sarcoma / Q000188:drug therapy; D013724:Teratoma / Q000188:drug therapy; D013736:Testicular Neoplasms / Q000188:drug therapy; D014748:Vinca Alkaloids / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D000903:Antibiotics, Antineoplastic; D009279:Naphthacenes; D014748:Vinca Alkaloids; D014750:Vincristine; D005047:Etoposide; D003606:Dacarbazine; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin; D007069:Ifosfamide